Drug Trial Radar · NCT07823205
A Study to Evaluate Different Oral Formulations of KT-621
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Kymera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.
Conditions
- Healthy Participants
Interventions
KT-621Drug
KT-621 Reference Oral Formulation
KT-621Drug
KT-621 Test Oral Formulation #1
KT-621Drug
KT-621 Test Oral Formulation #2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of KT-621Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)
- Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of KT-621Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)
- Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC∞) of KT-621Time frame: Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.